louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01622166: Art Therapy in Acute Schizophrenia
Official title: Art Therapy for Symptom Reduction in Acute Schizophrenia - a Randomised Controlled Trial (Kunsttherapie Zur Symptomreduktion Bei Akuter Schizophrenie - Eine Randomisierte Kontrollierte Pilotstudie)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schizophrenia
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
Collaborators: name: Prof. K. Dannecker, Kunsttherapie Berlin Kunsthochschule Berlin-Weißensee
First posted: 2012-06-19
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomised, controlled, single-blinded pilot study to assess the efficacy of psychodynamic art therapy in a sample of hospitalized, (sub)acutely psychotic patients with a diagnosis of schizophrenia compared to a group of patients receiving treatment as usual.

\*Main hypothesis: Art therapy has no impact on clinical symptoms and the course of remission compared to TAU.

\*Exploratory hypotheses: Art therapy has no influence on quality of life, mentalizing function, self-efficacy and neuroleptic dosage compared to TAU.


Eligibility criteria: Inclusion Criteria:

* diagnosis of schizophrenia according to DSM-IV-TR
* age 18-64 yrs
* sufficient German language competency
* written informed consent

Exclusion Criteria:

* axis-I mental disorders other than schizophrenia
* comorbid antisocial personality disorder, relevant substance abuse,
* relevant severe somatic disease
* acute suicidal tendencies or aggression
* incapability to tolerate group settings

Primary outcomes:
measure: Change in Positive and Negative Syndrome Scale (PANSS-) scores
timeFrame: weeks 0, 6, 12
measure: safety measures
timeFrame: weeks 0, 6, 12
measure: Change in Calgary depression Scale (CDS-) scores
timeFrame: weeks 0, 6, 12
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Psychiatrische Universitätsklinik der Charité im St. Hedwig Krankenhaus
Study officials:
affiliation: Charite University, Berlin, Germany
name: Christiane Montag, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Montag C, Haase L, Seidel D, Bayerl M, Gallinat J, Herrmann U, Dannecker K. A pilot RCT of psychodynamic group art therapy for patients in acute psychotic episodes: feasibility, impact on symptoms and mentalising capacity. PLoS One. 2014 Nov 13;9(11):e112348. doi: 10.1371/journal.pone.0112348. eCollection 2014.
Clinical trial NCT03500666: Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection
Official title: A Comparative Study of Robot Assisted BABA Approach and Chest Breast Approach for Lateral Neck Dissection
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Thyroid Carcinoma
Robot Surgery
Endoscopic Surgery
Keywords: Thyroid carcinoma
Robot surgery
Endoscopic surgery
Lead sponsor: Fujian Medical University
Sponsor class: OTHER
First posted: 2018-04-18
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective to compare the advantages and disadvantages of robotic and conventional endoscopic thyroidectomy for thyroid cancer.

Detailed description: To compare the difference of operative time and complication between two operative methods in robot neck surgery and routine endoscopic surgery.

Eligibility criteria: Inclusion Criteria:

1. papillary thyroid carcinoma with clinically suspected or confirmed lateral lymph node metastasis;
2. patient's concerns of neck scars and cosmetic requirement.

The exclusion criteria were as follows:

1) tumor size \>4cm; 2) previous neck surgical history； 3）residual or recurrent tumors; 4) suspicious primary tumor or metastatic lymph node invasion of major vascular structures or recurrent laryngeal nerve.

5）metastatic lymph nodes occurred below the sternoclavicular joint.

Primary outcomes:
measure: Lateral cervical lymph node cleaning time
timeFrame: During surgery
measure: Accessory nerve injury
timeFrame: During surgery
measure: Intraoperative internal jugular vein bleeding.
timeFrame: 6 months after surgery
Secondary outcomes:
measure: The time of the thyroid gland removal
timeFrame: During surgery
measure: Number of participants with HypoParathyroidism
timeFrame: 6 months after surgery
measure: Recurrent laryngeal nerve injury.
timeFrame: 6 months after surgery
Other outcomes:
Locations:
city: FuZhou
country: China
facility: Fujian Medical University Union Hospital
state: Fujian
city: Fuzhou
country: China
facility: Wen-xin ZHAO
state: Fujian
Study officials:
References:
Clinical trial NCT03447366: Mitral Doppler as a Predictor of Respiratory Worsening After Vascular Filling
Official title: Assessment of Mitral Doppler as a Predictor of Respiratory Worsening After Vascular Filling for ICU Patients With Mechanical Ventilation. The EVALDM Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Respiration, Artificial
Vascular Filling
Echocardiography
Lead sponsor: Centre Hospitalier Metropole Savoie
Sponsor class: OTHER
First posted: 2018-02-27
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Interventional study of the accuracy of a non-invasive testing by echocardiography to predict respiratory worsening after vascular filling.

Detailed description: Mitral Doppler will be performed before vascular filling. Patients will be classified in two groups (normal or high cardiac filling pressure).

The evolution of the respiratory data (SpO2/FiO2) of the two groups of the patients before and after vascular filling will be compared.

Eligibility criteria: Inclusion Criteria:

* Mechanical ventilation
* And hemodynamic failure
* And decision of the attending physician to perform a vascular filling

Exclusion Criteria:

* Pregnancy and breast-feeding women
* Patients deprived of their administrative or judicial freedom

Primary outcomes:
measure: frequency of the occuring of premature degradation respiratory
timeFrame: 30 minutes after vascular filling
Secondary outcomes:
Other outcomes:
Locations:
city: Bourg-en-Bresse
country: France
facility: Ch Bourg En Bresse
city: Chambéry
country: France
facility: Centre Hospitalier Metropole Savoie
city: La Tronche
country: France
facility: CHU Grenoble Alpes
Study officials:
References:
Clinical trial NCT05606666: Reliability of the Neurophysiology of Pain Questionnaire in the Neck Pain the Cross-validation Study
Official title: Reliability of the Neurophysiology of Pain Questionnaire in the Neck Pain the Cross-validation Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Neck Pain
Pain Knowledge
Keywords: neck pain
neurophysiology of pain
pain knowledge
pain education
Lead sponsor: Istanbul Arel University
Sponsor class: OTHER
First posted: 2022-11-07
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Persons who meet the inclusion criteria and who volunteered to participate in the study

Brief summary: The aim of this study is to study the validity and reliability of the Modified Pain Neurophysiology Questionnaire in patients with neck pain. After the ethics committee approval, women and men in Turkey will be invited to the research via online advertisements (researchers' facebook, instagram, twitter accounts). The scale will be translated from English to Turkish by two people who are fluent in Turkish and English. A single Turkish translation will be obtained with a common opinion from these two Turkish translations. In ten trial phases, a preliminary assessment will be conducted with 15 participants to test the intelligibility of the scale. If there are participants who think that there is a problem with the intelligibility of the scale, they will be asked to explain which items they have problems understanding and why. After individuals are informed with the online voluntary consent form, participants will be asked to complete the Modified Pain Neurophysiology questionnaire. Modified Pain Neurophysiology scale questions and questions in the data collection form will be prepared through the google surveys application and will be sent to the participants via Whatsapp, Facebook, Instagram and e-mail. Participants will fill out the survey forms online. In order to evaluate the validity of the Modified Pain Neurophysiology questionnaire, the pain subscale of the SF-36 scale, which has been validated in Turkish, will be used (McHorney, Ware, Lu, and Sherbourne, 1994), (Kocyigit et al., 1999). Scales after 15 days to assess test-retest reliability will be repeated.


Eligibility criteria: Inclusion Criteria:

* be between the ages of 18-65
* Having neck pain complaints for the last 3 months
* Adult individuals who agreed to participate in the study. Their mother tongue is Turkish.

Exclusion Criteria:

* Not answering all the questions

Primary outcomes:
measure: pain subscale of the SF-36 questionnaire
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: İstanbul
Study officials:
References:
Clinical trial NCT00184366: Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis
Official title: Classification and Characterization of Patients Suffering From Moderate to Severe Plaque Psoriasis Responding to Subcutaneous Administered Efalizumab
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Plaque Psoriasis
Keywords: drug therapy
efalizumab
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
First posted: 2005-09-16
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients of both genders, over the age of 18 years who have been suffering from moderate to severe plaque psoriasis for more than six months and who are eligible for efalizumab treatment according to current Norwegian guidelines.

Brief summary: The main objectives of the project are:

* To classify patients suffering from plaque psoriasis responding on a given treatment (efalizumab) based upon reduction in Psoriasis Area and severity Index (PASI), Psoriasis Disability Index 8PDI) and dermatology Life Quality Index 8 DLQI)
* To characterize patients suffering from plaque psoriasis responding to or not responding to subcutaneous administrated efalizumab.

Detailed description: This is an investigator initiated,prospective, longitudinal, observation study. Before starting treatment with efalizumab we will record factors such as demographic data, type of psoriasis, previous treatment, other diseases etc.

We will follow the patients and classify them as responders and non-responders. We hope to find 4-5 factors which we can use later to predict response of this drug.

Eligibility criteria: Inclusion Criteria:

* moderate to severe plaque psoriasis for more than six months
* eligible for efalizumab treatment according to current Norwegian guidelines

Exclusion Criteria:

* Pregnant or breast-feeding patients
* Patients with a history of uncontrolled bacterial, viral, fungal or atypical mycobacterial infection.
* Patients suffering from HIV, Hepatitis B or C, active tuberculosis, hepatic cirrhosis and hospital admission for cardiac disease, stroke or pulmonary disease within last year.
* Patients with history of cancer in the preceding 5 years, including lymphoproliferative disorders. patients with history of fully resolved basal cell or squamous cell skin cancer may be enrolled.
* Patients with impaired renal or hepatic function.

Primary outcomes:
measure: Response PASI 75
timeFrame: 2 years
Secondary outcomes:
measure: Dermatology Life Quality index (DLQI)
timeFrame: 2 years
measure: Psoriasis disability Index (PDI)
timeFrame: 2 years
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: Dep of dermatology, St Olavs Hospital
Study officials:
affiliation: St Olavs hospital, NTNU, Norway
name: Morten Dalaker, univ lekt II
role: STUDY_CHAIR
References:
Clinical trial NCT04792866: 3D FLAIR Versus Coronal T2-WI MRI in Detecting Optic Neuritis (FLACON)
Official title: 3D FLAIR Versus Coronal T2-WI MRI in Detecting Optic Neuritis in Patients Presenting With Acute Visual Loss and Otherwise Normal Ophthalmological Examination
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Optic Neuritis
Multiple Sclerosis
Encephalopathy
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2021-03-11
Enrollment: 1200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients presenting with acute visual loss and explored by MRI

Brief summary: 3D FLAIR, 3D T1 FAT SAT, coronal T2 and coronal T1 dixon sequences were usually used to assess visual deficits in MRI. Optic nerve examination is preferably performed using a coronal T2 sequence in order to detect a hypersignal suggestive of inflammation whereas brain examination is preferably performed using a 3D FLAIR sequence to highlight signs of spatial dissemination and lesions suggestive of multiple slerosis (MS).

Recently, a study based on a small number of patients showed the interest of 3D FLAIR in the detection of the hypersignal of the optic nerve.The objective of this retrospective study is to determine whether a single 3D FLAIR sequence allows simultaneous exploration of the optic nerve and the brain for the positive diagnosis of optic neuropathy and/or MS.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Decrease in visual acuity explored in MRI between january 2018 and january 2020

Exclusion Criteria:

* Past history of episode of Optic neuritis

Primary outcomes:
measure: Detection of optic neuropathies using MRI
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital Fondation Adolphe de Rothschild
state: Ile-de-France
Study officials:
References:
Clinical trial NCT03477266: Mouth Dissolving Mosapride Tables Enhance Post Cesarean Gut Recovery
Official title: Effectiveness of Mouth Dissolving Mosapride Tablets on Enhancing Gut Recovery After Cesarean Section: Randomized Double-blind, Placebo-controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Prevention of Postoperative Ileus
Keywords: Postoperative ileus
mosapride
mouth dissolving tablets
Intraoperative vomiting
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2018-03-26
Enrollment: 400
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Giving women one day before and immediately after cesarean section a mouthly dissolving mosapride tablets 2every every 8 hours for maximum of 5 days ,or getting recovered gastrointestinal functions And assess preoperative gastrointestinal functions

Detailed description: Uncomplicated post cesarean women one day before and immediately after elective cesarean receive 2 mouthly dissolving mosapride tablets every 8 hours maximum for 5 days and clinical care giver follow the woman's gastrointestinal functions, including intraoperative and postoperative nausea vomiting, passing flatus, hearing intestinal sounds, passing stools, occurring of paralytic ileus, length of the hospital stay

Eligibility criteria: Inclusion Criteria:

* all women undergoing elective cesarean section

Exclusion Criteria:

* prior abdominal surgery, abdominal adhesion, chronic constipation, allergy to mosapride

Primary outcomes:
measure: Time of first flatus
timeFrame: 96 hours postoperative
Secondary outcomes:
measure: Paralytic ileus incidence and its severity
timeFrame: 7days
measure: Toleration of fluids and solids intake
timeFrame: 2 weeks postoperative
measure: Incidence of intraoperative and postoperative nausea and vomiting
timeFrame: Intraoperative and 2 weeks postoperative
measure: First defecation
timeFrame: 2 weeks postoperative
Other outcomes:
Locations:
city: Banha
country: Egypt
facility: Ashraf nassif Elmantwe
state: Elqalopia
Study officials:
affiliation: Benha University
name: Ashraf N Elmantwe, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06836466: Physicians' Awareness of ECG Abnormalities Linked to Acute Ischemic Chest Pain
Official title: Physicians' Awareness of ECG Abnormalities Linked to Acute Ischemic Chest Pain; A Survey Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Physicians
Awareness
ECG Abnormalities
Acute Ischemic Chest Pain
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2025-02-20
Enrollment: 500
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A consecutive sample of 500 physicians who treat patients with possible acute ischemic chest pain will be the subject of this cross-sectional survey study. These doctors will include emergency physicians, cardiologists, internal medicine/acute medicine specialists, general practice or family physicians, anesthesiologists, and intensive care physicians of both sexes, with varying degrees of experience and post-graduate clinical training, from all over the world.

Brief summary: This study aims to investigate physicians' awareness regarding patients presenting with potential acute ischemic chest pain. It focuses on various electrocardiogram (ECG) patterns requiring prompt catheter lab activation for reperfusion therapy alongside other ECG mimics that may lead to false catheter lab activations.

Detailed description: Chest pain is the second most common complaint in adult emergency department (ED) patients in the United States. Most visits result in a diagnosis of noncardiac chest pain and approximately half in nonspecific chest pain. Roughly 6% are ultimately diagnosed with a life-threatening condition, which is overwhelmingly (\>90%) acute coronary syndrome (ACS).

The term acute coronary syndrome (ACS) is applied to patients in whom there is a suspicion or confirmation of acute myocardial ischemia or infarction. ST-elevation myocardial infarction (STEMI), Non-ST-elevation MI (NSTEMI), and unstable angina are the three traditional types of ACS.

Eligibility criteria: Inclusion Criteria:

* Age from 25 to 65 years.
* Both sexes.
* Physicians who treat patients with possible acute chest pain.

Exclusion Criteria:

- Participants who failed to complete the survey questions.

Primary outcomes:
measure: Physicians' Awareness
timeFrame: At time of online survey (Up to 2 months)
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
state: El-Gharbia
Study officials:
References:
Clinical trial NCT04557566: ED Recovery Course Online RCT
Official title: A Randomized Controlled Trial of the Eat Breathe Thrive Yoga for Eating Disorder Recovery Online Course
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Yoga-Based Recovery Course
Control
Lead sponsor: University at Buffalo
Sponsor class: OTHER
Collaborators: name: Eat Breathe Thrive
First posted: 2020-09-21
Enrollment: 277
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: RCT- EBT Yoga-Based Course and Control group
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to examine whether the Eat Breathe Thrive (EBT) Yoga for Eating Disorder Recovery online course is effective in supporting eating disorder recovery.

Detailed description: We will conduct a block randomized controlled trial (RCT) comparing an intervention group and a waitlist control group. Participants in the intervention group will complete the Eat Breathe Thrive (EBT) Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study. At Pretest, Posttest 1, Posttest 2, and three-months Follow-Up, participants will complete a series of self-report measures (see point 12.3). Participants in the waitlist control group will only be engaged in the study assessment procedures. However, they will be given the opportunity to take part in the Yoga for Eating Disorder Recovery online course that was delivered to the intervention group, once Posttest 1 has been completed by both groups.

Eligibility criteria: Inclusion Criteria:

* Participants included in the study sample will be people between the ages of 18 and 65, who self-identify as women, are not pregnant, are willing to sign the consent form, are English-speakers, have not taken any EBT course before, and self-identify as recovering from an eating disorder.

Exclusion Criteria:

* The study will utilize the EBT participant application for screening (see attached). Further, those excluded will be people who do not self-identify as women, who are below 18 years old or above 65, pregnant, unable/refuse to sign the consent form, non-English speakers, have taken EBT before, and who do not self-identify as recovering from an eating disorder. Further, those who have suicidal ideations and engage in self-harm behaviors cannot be included.

Primary outcomes:
measure: Reduced Eating Disorder Behaviors
timeFrame: at 4, 12, and 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Buffalo
country: United States
facility: University at Buffalo, SUNY
state: New York
Study officials:
References: